Intrinsic Value of S&P & Nasdaq Contact Us

Humana Inc. HUM NYSE

NYSE • Healthcare • Medical - Healthcare Plans • US • USD

SharesGrow Score
53/100
2/7 Pass
SharesGrow Intrinsic Value
$1,449.84
+638.9%
Analyst Price Target
$235.00
+19.8%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Humana Inc. (HUM) trades at a trailing P/E of 19.8, forward P/E of 21.7. Trailing earnings yield is 5.05%, forward earnings yield 4.61%. PEG 0.47 (Peter Lynch undervalued ≤1.0). Graham Number is $180.94.

Criteria proven by this page:

  • VALUE (86/100, Pass) — P/E is below market average (19.8); PEG ≤ 1.0 — Peter Lynch undervalued (0.47); analyst target implies upside (+19.8%); earnings yield beats bond yields (5.05%).
  • PEG Ratio 0.47 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield 5.05% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
  • Analyst consensus target $235.00 (+19.8% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
53/100
SG Score
View full scorecard →
VALUE
86/100
Price-to-Earnings & upside
Proven by this page
~
FUTURE
46/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
17/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
45/100
→ Income
~
GROWTH
48/100
→ Income
INCOME
30/100
→ Income

Valuation Snapshot — HUM

Valuation Multiples
P/E (TTM)19.8
Forward P/E21.7
PEG Ratio0.47
Forward PEG0.47
P/B Ratio1.33
P/S Ratio0.18
EV/EBITDA11.1
Per Share Data
EPS (TTM)$9.87
Forward EPS (Est.)$9.05
Book Value / Share$147.39
Revenue / Share$1,077.49
FCF / Share$3.12
Yields & Fair Value
Earnings Yield5.05%
Forward Earnings Yield4.61%
Dividend Yield1.81%
Graham Number$180.94
SharesGrow IV$1,449.84 (+638.9%)
Analyst Target$235.00 (+19.8%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 49.6 -0.96 2.85 0.56 0.58%
2017 14.6 0.05 3.64 0.67 0.61%
2018 23.4 -0.84 3.88 0.69 0.67%
2019 18.2 0.28 4.08 0.76 0.59%
2020 16.1 0.62 3.95 0.70 0.60%
2021 20.4 -1.93 3.71 0.71 0.59%
2022 23.1 -8.91 4.23 0.70 0.61%
2023 22.8 -2.40 3.49 0.53 0.76%
2024 25.3 -0.51 1.87 0.26 1.41%
2025 26.0 -18.57 1.75 0.24 1.39%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $4.07 $54.38B $614M 1.1%
2017 $16.81 $53.77B $2.45B 4.6%
2018 $12.16 $56.91B $1.68B 3%
2019 $20.10 $64.89B $2.71B 4.2%
2020 $25.31 $77.16B $3.37B 4.4%
2021 $22.67 $83.06B $2.93B 3.5%
2022 $22.08 $92.87B $2.81B 3%
2023 $20.00 $106.37B $2.49B 2.3%
2024 $9.98 $117.76B $1.21B 1%
2025 $9.84 $129.66B $1.19B 0.9%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $9.22 $7.79 – $12.83 $160.62B $140.09B – $168.25B 16
2027 $15.28 $11.97 – $19.25 $170.67B $149.15B – $183.95B 15
2028 $26.71 $18.98 – $36.14 $183.11B $182.44B – $183.77B 7
2029 $38.84 $32.40 – $42.06 $192.72B $168.13B – $205.03B 2
2030 $41.63 $34.72 – $45.09 $204.44B $178.35B – $217.49B 5
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message